(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) said yesterday it has awarded contracts to two companies to develop vaccines based on the H5N1 avian influenza virus in an effort to limit the risk of a human influenza pandemic.
(CIDRAP News) In a bid to limit the threat of an influenza pandemic, the Department of Health and Human Services (HHS) is awarding a contract to Aventis Pasteur Inc. to make 2 million doses of a vaccine for humans to protect against H5N1 avian influenza.
(CIDRAP News) Clinical trials of a vaccine designed to keep the H5N1 avian influenza virus from sparking a human flu pandemic will begin early in 2005, the head of the National Institute of Allergy and Infectious Diseases (NIAID) said this week.
(CIDRAP News) Live-virus vaccines made from a combination of H5N1 avian influenza virus and another flu strain protected laboratory mice and ferrets from deadly infection with several different H5N1 strains, according to a report published yesterday.
(CIDRAP News) Scientists reported yesterday that an experimental vaccine triggered a good immune response to H9N2 avian influenza virus, a type that has caused a few human infections and is considered capable of evolving into a pandemic strain.
(CIDRAP News) The human immune system may respond better to a vaccine for a new strain of H5N1 avian influenza if it is prepared in advance with a vaccine based on an existing H5N1 strain, the preliminary results of a government-sponsored study suggest.
(CIDRAP News) Hong Kong officials have reported that a 9-month-old girl is infected with the strain of avian influenza known as A/H9N2, which has caused mild human illness in the city three times before and is considered capable of evolving into a pandemic strain.
(CIDRAP News) – In a major effort to track influenza viruses in nature and learn more about how they interact with the human body, the federal government this week announced a $23-million-a-year program to fund research centers at six institutions around the country.